Assessment of the effectiveness of Intravitreal anti-vascular endothelial growth factor on lowering intraocular pressure in early Neovascular glaucoma
Abdelrahman abdelaal, N., ElGoweini, H., El Hofi, A., Gomaa, A. (2020). Assessment of the effectiveness of Intravitreal anti-vascular endothelial growth factor on lowering intraocular pressure in early Neovascular glaucoma. EKB Journal Management System, 2(2), 59-59. doi: 10.21608/alexpo.2020.47195.1058
Nashwa Mohamed Abdelrahman abdelaal; Hesham ElGoweini; Abd El Hamid Shaker El Hofi; Amir Ramadan Gomaa. "Assessment of the effectiveness of Intravitreal anti-vascular endothelial growth factor on lowering intraocular pressure in early Neovascular glaucoma". EKB Journal Management System, 2, 2, 2020, 59-59. doi: 10.21608/alexpo.2020.47195.1058
Abdelrahman abdelaal, N., ElGoweini, H., El Hofi, A., Gomaa, A. (2020). 'Assessment of the effectiveness of Intravitreal anti-vascular endothelial growth factor on lowering intraocular pressure in early Neovascular glaucoma', EKB Journal Management System, 2(2), pp. 59-59. doi: 10.21608/alexpo.2020.47195.1058
Abdelrahman abdelaal, N., ElGoweini, H., El Hofi, A., Gomaa, A. Assessment of the effectiveness of Intravitreal anti-vascular endothelial growth factor on lowering intraocular pressure in early Neovascular glaucoma. EKB Journal Management System, 2020; 2(2): 59-59. doi: 10.21608/alexpo.2020.47195.1058

Assessment of the effectiveness of Intravitreal anti-vascular endothelial growth factor on lowering intraocular pressure in early Neovascular glaucoma

ALEXMED ePosters
Article 25, Volume 2, Issue 2, October 2020, Page 59-59  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2020.47195.1058
View on SCiNiTO View on SCiNiTO
Authors
Nashwa Mohamed Abdelrahman abdelaal email 1; Hesham ElGoweini2; Abd El Hamid Shaker El Hofi2; Amir Ramadan Gomaa3
1Ophthalmology department,faculty of medicine, Alexandria University, Alexandria, Egypt
2Ophthalmology department, faculty of medicine, Alexandria University, Alexandria, Egypt
3ophthalmology department Alexandria university
Abstract
Neovascular glaucoma (NVG) is a serious refractory form of secondary glaucoma with poor prognosis characterized by iris and iridocorneal neovascularization and increase intraocular pressure. The underlying pathogenesis in most cases is posterior segment ischemia such as proliferative diabetic retinopathy, central retinal vein occlusion, ocular ischemic syndrome. Neovascularization in the eye occurs due to an imbalance between pro-angiogenic factors as vascular endothelial growth factor VEGF and other anti-angiogenic factors as pigment-epithelium- derived factor. Therefore, anti –VEGF antibody may serve as a useful adjunctive to the therapy of NVG via its antiangiogenic anti fibroblastic properties. It lead to regression of both iris and angle neovascularization, and controlling intraocular pressure
The management of NVG is approached by first treating the underlying condition responsible for the neovascular stimulus. This can be achieved by panretinal photocoagulation and intravitreal anti VEGF. Secondarily Controlling the elevated IOP which may lead to progressive optic neuropathy if untreated either medically or surgically
Keywords
Neovascular glaucoma; Anti-VEGF therapy; Iris neovascularization
Statistics
Article View: 177